Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study

Last updated: March 2, 2022
Sponsor: Soroka University Medical Center
Overall Status: Completed

Phase

2

Condition

Atopic Dermatitis

Allergy

Eczema (Atopic Dermatitis)

Treatment

N/A

Clinical Study ID

NCT05276323
SorokaUMC
  • Ages 2-18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

A randomized, open-label trial comparing Medihoney Derma Cream to Hydrocortisone 1% cream. Children between the ages of 2-18 years old diagnosed with mild to moderate atopic dermatitis with an IGA (Investigator Global Assessment) score of 2-3, and a BSA (Body Surface Area) score of 1%-10% were included.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 2-18 years old
  • mild to moderate atopic dermatitis
  • an IGA score of 2-3
  • BSA score of 1%-10%.

Exclusion

Exclusion Criteria:

  • participation in any clinical trial less than 28 days before the enrollment
  • AD-related systemic therapy or phototherapy within 28 days prior to the enrollment
  • topical corticosteroids, calcineurin inhibitors, or PDE4 inhibitors use within 7 daysprior to the enrollment

Study Design

Total Participants: 30
Study Start date:
October 01, 2020
Estimated Completion Date:
December 31, 2021

Study Description

A randomized trial comprising children aged 2-18 diagnosed with mild to moderate AD, with an IGA of 2-3 and BSA of 1%-10%, including 30 patients, 20 using Med-D-Cream and 10 as controls using Hydrocortisone 1% cream. Patients applied creams for 2 weeks and were then followed for two weeks to measure clinical responses and pruritus change.

Connect with a study center

  • Soroka University Medical Center

    Beer Sheva,
    Israel

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.